Spectral Analyses and Structural Elucidation of Azilsartan

doi:10.11938/cjmr20182689

Abstract

Abstract: Azilsartan is a novel AT-1 angiotensin Ⅱ receptor blocker, which reduces blood pressure mildly without the side effect of cough. The drug is believed to have a large market potential. In this study, the drug was analyzed by ultraviolet spectroscopy (UV), infrared spectroscopy (IR), high resolution mass spectrometry (HRMS) and one-/two-dimensional magnetic resonance spectroscopy (i.e., ¹H NMR, ¹³C NMR, DEPT, ¹H-¹H COSY, HMQC and HMBC). The spectral data were carefully analyzed, interpreted and used to elucidate the structure of the compound.

Key words: nuclear magnetic resonance (NMR), assignment, chemical shift, azilsartan, structure elucidation

CLC Number:

O482.53

WANG Ya-lan, WANG Xiao-jing, WANG Zhi-wei. Spectral Analyses and Structural Elucidation of Azilsartan[J]. Chinese Journal of Magnetic Resonance, 2019, 36(3): 350-358.

References

[1] WHTE W B, WEBER M A, SICA D, et al. Effects of the angiotensin receptor blocker azilasartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension[J]. Hypertension, 2011, 57(3):413-420.
[2] KOHARA Y, IMAMIYA E, KUBO K, et al. A new class of angiotensin Ⅱ receptor antagonists with a novel acidic bioisostere[J]. Bioorg Med Chem Lett, 1995, 5(17):1903-1908.
[3] BAKER W L, WHITE W B. Azilsartan medoxomil:a new angiotensin Ⅱ receptor antagonist for treatment of hypertension[J]. Ann Pharmacother, 2011, 45(12):1506-1515.
[4] BÖNNER G, BAKRIS G L, SICA D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril[J]. J Hum Hypertens, 2013, 27(8):479-486.
[5] HANDLEY A, LLOYD E, ROBERTS A, et al. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension:a one-year, phase 3, open-label study[J]. Clin Exp Hypertens, 2016, 38(2):180-188.
[6] ZHAO C Y, WANG J J, LIU Y, et al. Pharmacology and clinical evaluation of edarbi, a new drug for the treatment of cardiovascular disease[J]. Chin J New Drug, 2011, 20(19):1831-1832. 赵春艳, 王京晶, 刘洋, 等. 心血管疾病新药阿齐沙坦酯的药理与临床评价[J]. 中国新药杂志, 2011, 20(19):1831-1832.
[7] 张盼晓. 阿齐沙坦酯治疗原发性高血压的安全性Meta分析[D]. 兰州:兰州大学, 2016.
[8] 韩世磊. 阿齐沙坦的合成工艺及质量研究[D]. 天津:天津大学, 2014.
[9] 赵艳艳. 阿齐沙坦及相关杂质的合成研究[D]. 石家庄:河北师范大学, 2017.
[10] 郭永斌. 阿齐沙坦片的制备及质量研究[D]. 石家庄:河北医科大学, 2016.
[11] SHU B Y, WU X S, CEN J D. Synthesis of azilsartan[J]. Chin J Pharm, 2010, 41(12):881-883.束蓓艳, 吴雪松, 岑均达. 阿齐沙坦的合成[J]. 中国医药工业杂志, 2010, 41(12):881-883.
[12] ZHENG Z H, ZHANG D M, WU H, et al. Synthesis of azilsartan[J]. Chemical Industry Times, 2015, 29(8):10-12,31.郑忠辉, 张代铭, 吴辉, 等. 阿齐沙坦的合成工艺研究[J]. 化工时刊, 2015, 29(8):10-12,31.
[13] SUI L P, LI R D, SONG B, et al. Characterization of two degradation products of azilsartan formed during the micronization process and development of a method to control the degradation[J]. J Chin Pharm Sci, 2014, 23(5):302-305.
[14] STANISLAV R, JOSEF C, JAN S, et al. Improved process for azilsartan medoxomil:a new angiotensin receptor blocker[J]. Org Process Res Dev, 2013, 17(1):77-86.
[15] STANISLAV R, JOSEF C, JAN S, et al. Synthesis of azilsartan and its selected potential impurities[J]. J Heterocyclic Chem, 2013, 50(4):929-936.
[16] LIN Y L, GAO H M, LI F, et al. Spectral analysis and structural elucidation of luliconazole[J]. Chinese J Magn Reson, 2018, 35(3):385-392.林云良, 高红梅, 李锋, 等. 卢立康唑的波谱学特征和结构确证[J]. 波谱学杂志, 2018, 35(3):385-392.
[17] ZHANG M G, FENG X H, YU S T, et al. Spectral analysis and structural elucidation of besifloxacin hydrochloride[J]. Chinese J Magn Reson, 2018, 35(3):374-384.张明光, 冯小虎, 于水涛, 等. 盐酸贝西沙星的波谱学数据与结构确证[J]. 波谱学杂志, 2018, 35(3):374-384.
[18] 杨和军. 抗高血压药阿齐沙坦及阿齐沙坦酯钾盐的合成工艺研究[D]. 杭州:浙江工业大学, 2017.